Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)

BIOLOGICAL4 trials

Sponsors

Jun Zhang, Xiamen University

Conditions

Cervical CancerCervical Intraepithelial NeoplasiaPersistent InfectionVaginal Intraepithelial NeoplasiaVulvar Intraepithelial Neoplasia

Unknown Phase

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Jun ZhangCervical Cancer, Cervical Intraepithelial Neoplasia, Persistent Infection +2

Start: 2021-02-06End: 2023-12-31Target: 979Updated: 2023-01-26

The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Jun ZhangCervical Cancer, Cervical Intraepithelial Neoplasia, Persistent Infection +2

Start: 2021-03-30End: 2024-01-31Target: 647Updated: 2023-01-26

The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Jun ZhangCervical Cancer, Cervical Intraepithelial Neoplasia, Persistent Infection +2

Start: 2021-04-13End: 2024-01-31Target: 1339Updated: 2023-01-26

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Active, not recruitingNCT06243666

Xiamen UniversityCervical Cancer, Cervical Intraepithelial Neoplasia, Persistent Infection

Start: 2024-02-20End: 2026-12-31Target: 2188Updated: 2025-07-31

Related Papers

Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years.

2026-01-14